NCT00328978

Seroquel STACK Study in Schizophrenic or Schizoaffective Subjects

A Canadian, Multicenter, Double-Blind, Randomized, Parallel-Group Study of the Safety, Tolerability, and Efficacy of Treatment With Higher Doses of Quetiapine Fumarate (Seroquel®) Greater Than 800 mg/Day in Schizophrenic or Schizoaffective Subjects.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 330 (planned)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to assess and compare the side effect profile, safety, tolerability and efficacy of schizophrenic or schizoaffective subjects non- or partially- responsive to 800 mg/day of quetiapine treated with either 800 mg/day or more than 800 mg/day of quetiapine during 8 weeks.

Conditions

• Schizophrenia
• Schizoaffective Disorders

Interventions

Type	Name	Description
DRUG	Quetiapine

Timeline

• Start date: 2003-10-01
• Completion: 2005-09-01
• First posted: 2006-05-24
• Last updated: 2009-03-25

Locations

17 sites across 1 country: Canada